H PLUS YANGJI HOSPITAL, Seoul
Seoul, South Korea
NCT Number: NCT07715305
The study compare and evaluate the bioequivalence between the administration of AD-116A and the administration of AD-1161 in healthy adult male volunteers
Trial opening soon.
Get Notified19 year and older
Male
Interventional
Phase 1
Seoul, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral Capsule
Oral Capsule
Time frame: pre-dose (0hour) to 72hours
AUCt of AD-116A
Time frame: pre-dose (0hour) to 72hours
Cmax of AD-116A
Contact information is provided by the study sponsor or research team.
Addpharma Inc.
Industry
An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers Under Fasting Conditions
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07736807
Benign Prostatic Hyperplasia, Genital Diseases
Nanjing, Jiangsu, China
View Trial DetailsNCT07722871
Benign Prostatic Hyperplasia, Genital Diseases
Seoul, South Korea
View Trial DetailsNCT07569874
Benign Prostatic Hyperplasia, Bladder Outlet Obstruction
Beijing, Beijing Municipality, China
View Trial DetailsNCT07619105
Benign Prostatic Hyperplasia, Genital Diseases
View Trial Details